For anyone taking resveratrol as a longevity supplement, the molecular form in their capsule may matter far more than the dose — and a new mechanistic discovery explains precisely why. The distinction between two structural mirror-image forms of this widely consumed polyphenol turns out to hinge on a single mitochondrial enzyme, with consequences reaching from fertility biology to neurodegenerative disease.
Resveratrol exists in two isomeric configurations — trans and cis — that interact with mitochondrial endonuclease G (EndoG) in diametrically opposed ways. EndoG is a nuclease residing in the mitochondrial intermembrane space that participates in two seemingly unrelated processes: paternal mitochondrial elimination (PME), the selective destruction of sperm-derived mitochondria after fertilization, and neuronal cell death pathways relevant to conditions like Parkinson's and Alzheimer's disease. The research team identified trans-resveratrol as a PME inhibitor operating through EndoG suppression, while its cis counterpart demonstrated the opposite functional profile at the same target. The work was conducted using biochemical assays and model organisms, establishing EndoG as a bifunctional molecular node connecting reproductive biology to neurodegeneration.
This finding carries several layers of significance for health-conscious adults. First, virtually all commercial resveratrol supplements are formulated as trans-resveratrol, the more stable isomer — yet this research suggests the two forms are not interchangeable and may in fact antagonize each other. Second, EndoG's dual role in PME and neuronal apoptosis raises the provocative possibility that optimizing mitochondrial quality-control pathways in neurons could have unintended reproductive biology implications, and vice versa. Third, while the mechanistic elegance here is compelling, the work appears to remain in preclinical territory; translating EndoG modulation into neuroprotective therapies in humans requires substantially more validation. This is nonetheless a potentially paradigm-shifting reframing of resveratrol's mechanism, moving beyond vague SIRT1 activation narratives toward a precise enzymatic target.
